Report Detail

Request for Sample of this report

Service & Software Global Exosome CDMO Market 2026 by Company, Regions, Type and Application, Forecast to 2032

  • RnM4675835
    • |
  • 20 February, 2026
    • |
  • Global
    • |
  • 125 Pages
    • |
  • GIR
    • |
  • Service & Software

According to our (Global Info Research) latest study, the global Exosome CDMO market size was valued at US$ 656 million in 2025 and is forecast to a readjusted size of US$ 1154 million by 2032 with a CAGR of 8.5% during review period.
Exosome CDMO refers to providing customized R&D and manufacturing services for biopharmaceutical companies across the entire exosome chain, from process development to large-scale production. Its core businesses encompass the construction and culture of exosome production cell lines, development of large-scale exosome extraction and purification processes, rigorous quality control and analysis (including purity, drug loading, and biological function), formulation development, and GMP-compliant manufacturing. This service aims to help clients address the technical, process scale-up, and compliance challenges they face in developing exosomes as drug carriers or therapeutic products, accelerating the translation from laboratory research to preclinical and clinical trials. It is an indispensable key support platform for the industrialization of exosome therapies.
The global Exosome CDMO market exhibits a distinct pattern of "technology leadership, regional concentration, and the rise of the Asia-Pacific region." North America (especially the United States) currently holds an absolute leading position, possessing the most mature GMP production system, the most cutting-edge engineering technology platform, and a dense customer base of early-stage biotechnology companies, dominating the global early-stage clinical trial supply chain. Europe, with its strong foundation in cell and gene therapy, boasts robust capabilities in process development and quality systems. The Asia-Pacific region (represented by China and South Korea) is the fastest-growing market globally. Leveraging its mature biopharmaceutical manufacturing ecosystem, relatively flexible service models, and rapid technological advancements, it is actively building a service system from process development to localized production, aiming to become a key node in the regional and even global supply chain. The industry as a whole is still in its early stages, rapidly evolving from fragmented research services to a standardized, large-scale pharmaceutical-grade industry.
This report is a detailed and comprehensive analysis for global Exosome CDMO market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Exosome CDMO market size and forecasts, in consumption value ($ Million), 2021-2032
Global Exosome CDMO market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Exosome CDMO market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Exosome CDMO market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Exosome CDMO
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Exosome CDMO market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include REPROCELL, Histocell, Lonza, MYCENAX, RoosterBio, Altaris LLC, Asahi Glass Co., Fortis Life Sciences, Scorpius BioManufacturing, Miltenyi Bioindustry, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Exosome CDMO market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Preclinical CRO
Clinical CRO
Market segment by Service Stage
Process Development Type
GMP Production Type
Analytical Testing and Quality Control Type
Market segment by Exosome Source
Natural Exosome CDMO
Engineered Exosome CDMO
Market segment by Application
Laboratory
Universities
Bio Industry
Medical Industry
Market segment by players, this report covers
REPROCELL
Histocell
Lonza
MYCENAX
RoosterBio
Altaris LLC
Asahi Glass Co.
Fortis Life Sciences
Scorpius BioManufacturing
Miltenyi Bioindustry
Exothera
EXO Biologics
Porton Advanced
Elise Biopharma
Evox Therapeutics
FUJIFILM Biotechnologies
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Exosome CDMO product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Exosome CDMO, with revenue, gross margin, and global market share of Exosome CDMO from 2021 to 2026.
Chapter 3, the Exosome CDMO competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Exosome CDMO market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Exosome CDMO.
Chapter 13, to describe Exosome CDMO research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Exosome CDMO by Type
    • 1.3.1 Overview: Global Exosome CDMO Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Exosome CDMO Consumption Value Market Share by Type in 2025
    • 1.3.3 Preclinical CRO
    • 1.3.4 Clinical CRO
  • 1.4 Classification of Exosome CDMO by Service Stage
    • 1.4.1 Overview: Global Exosome CDMO Market Size by Service Stage: 2021 Versus 2025 Versus 2032
    • 1.4.2 Global Exosome CDMO Consumption Value Market Share by Service Stage in 2025
    • 1.4.3 Process Development Type
    • 1.4.4 GMP Production Type
    • 1.4.5 Analytical Testing and Quality Control Type
  • 1.5 Classification of Exosome CDMO by Exosome Source
    • 1.5.1 Overview: Global Exosome CDMO Market Size by Exosome Source: 2021 Versus 2025 Versus 2032
    • 1.5.2 Global Exosome CDMO Consumption Value Market Share by Exosome Source in 2025
    • 1.5.3 Natural Exosome CDMO
    • 1.5.4 Engineered Exosome CDMO
  • 1.6 Global Exosome CDMO Market by Application
    • 1.6.1 Overview: Global Exosome CDMO Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.6.2 Laboratory
    • 1.6.3 Universities
    • 1.6.4 Bio Industry
    • 1.6.5 Medical Industry
  • 1.7 Global Exosome CDMO Market Size & Forecast
  • 1.8 Global Exosome CDMO Market Size and Forecast by Region
    • 1.8.1 Global Exosome CDMO Market Size by Region: 2021 VS 2025 VS 2032
    • 1.8.2 Global Exosome CDMO Market Size by Region, (2021-2032)
    • 1.8.3 North America Exosome CDMO Market Size and Prospect (2021-2032)
    • 1.8.4 Europe Exosome CDMO Market Size and Prospect (2021-2032)
    • 1.8.5 Asia-Pacific Exosome CDMO Market Size and Prospect (2021-2032)
    • 1.8.6 South America Exosome CDMO Market Size and Prospect (2021-2032)
    • 1.8.7 Middle East & Africa Exosome CDMO Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 REPROCELL
    • 2.1.1 REPROCELL Details
    • 2.1.2 REPROCELL Major Business
    • 2.1.3 REPROCELL Exosome CDMO Product and Solutions
    • 2.1.4 REPROCELL Exosome CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 REPROCELL Recent Developments and Future Plans
  • 2.2 Histocell
    • 2.2.1 Histocell Details
    • 2.2.2 Histocell Major Business
    • 2.2.3 Histocell Exosome CDMO Product and Solutions
    • 2.2.4 Histocell Exosome CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Histocell Recent Developments and Future Plans
  • 2.3 Lonza
    • 2.3.1 Lonza Details
    • 2.3.2 Lonza Major Business
    • 2.3.3 Lonza Exosome CDMO Product and Solutions
    • 2.3.4 Lonza Exosome CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Lonza Recent Developments and Future Plans
  • 2.4 MYCENAX
    • 2.4.1 MYCENAX Details
    • 2.4.2 MYCENAX Major Business
    • 2.4.3 MYCENAX Exosome CDMO Product and Solutions
    • 2.4.4 MYCENAX Exosome CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 MYCENAX Recent Developments and Future Plans
  • 2.5 RoosterBio
    • 2.5.1 RoosterBio Details
    • 2.5.2 RoosterBio Major Business
    • 2.5.3 RoosterBio Exosome CDMO Product and Solutions
    • 2.5.4 RoosterBio Exosome CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 RoosterBio Recent Developments and Future Plans
  • 2.6 Altaris LLC
    • 2.6.1 Altaris LLC Details
    • 2.6.2 Altaris LLC Major Business
    • 2.6.3 Altaris LLC Exosome CDMO Product and Solutions
    • 2.6.4 Altaris LLC Exosome CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Altaris LLC Recent Developments and Future Plans
  • 2.7 Asahi Glass Co.
    • 2.7.1 Asahi Glass Co. Details
    • 2.7.2 Asahi Glass Co. Major Business
    • 2.7.3 Asahi Glass Co. Exosome CDMO Product and Solutions
    • 2.7.4 Asahi Glass Co. Exosome CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Asahi Glass Co. Recent Developments and Future Plans
  • 2.8 Fortis Life Sciences
    • 2.8.1 Fortis Life Sciences Details
    • 2.8.2 Fortis Life Sciences Major Business
    • 2.8.3 Fortis Life Sciences Exosome CDMO Product and Solutions
    • 2.8.4 Fortis Life Sciences Exosome CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Fortis Life Sciences Recent Developments and Future Plans
  • 2.9 Scorpius BioManufacturing
    • 2.9.1 Scorpius BioManufacturing Details
    • 2.9.2 Scorpius BioManufacturing Major Business
    • 2.9.3 Scorpius BioManufacturing Exosome CDMO Product and Solutions
    • 2.9.4 Scorpius BioManufacturing Exosome CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Scorpius BioManufacturing Recent Developments and Future Plans
  • 2.10 Miltenyi Bioindustry
    • 2.10.1 Miltenyi Bioindustry Details
    • 2.10.2 Miltenyi Bioindustry Major Business
    • 2.10.3 Miltenyi Bioindustry Exosome CDMO Product and Solutions
    • 2.10.4 Miltenyi Bioindustry Exosome CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Miltenyi Bioindustry Recent Developments and Future Plans
  • 2.11 Exothera
    • 2.11.1 Exothera Details
    • 2.11.2 Exothera Major Business
    • 2.11.3 Exothera Exosome CDMO Product and Solutions
    • 2.11.4 Exothera Exosome CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Exothera Recent Developments and Future Plans
  • 2.12 EXO Biologics
    • 2.12.1 EXO Biologics Details
    • 2.12.2 EXO Biologics Major Business
    • 2.12.3 EXO Biologics Exosome CDMO Product and Solutions
    • 2.12.4 EXO Biologics Exosome CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 EXO Biologics Recent Developments and Future Plans
  • 2.13 Porton Advanced
    • 2.13.1 Porton Advanced Details
    • 2.13.2 Porton Advanced Major Business
    • 2.13.3 Porton Advanced Exosome CDMO Product and Solutions
    • 2.13.4 Porton Advanced Exosome CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Porton Advanced Recent Developments and Future Plans
  • 2.14 Elise Biopharma
    • 2.14.1 Elise Biopharma Details
    • 2.14.2 Elise Biopharma Major Business
    • 2.14.3 Elise Biopharma Exosome CDMO Product and Solutions
    • 2.14.4 Elise Biopharma Exosome CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 Elise Biopharma Recent Developments and Future Plans
  • 2.15 Evox Therapeutics
    • 2.15.1 Evox Therapeutics Details
    • 2.15.2 Evox Therapeutics Major Business
    • 2.15.3 Evox Therapeutics Exosome CDMO Product and Solutions
    • 2.15.4 Evox Therapeutics Exosome CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.15.5 Evox Therapeutics Recent Developments and Future Plans
  • 2.16 FUJIFILM Biotechnologies
    • 2.16.1 FUJIFILM Biotechnologies Details
    • 2.16.2 FUJIFILM Biotechnologies Major Business
    • 2.16.3 FUJIFILM Biotechnologies Exosome CDMO Product and Solutions
    • 2.16.4 FUJIFILM Biotechnologies Exosome CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.16.5 FUJIFILM Biotechnologies Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Exosome CDMO Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Exosome CDMO by Company Revenue
    • 3.2.2 Top 3 Exosome CDMO Players Market Share in 2025
    • 3.2.3 Top 6 Exosome CDMO Players Market Share in 2025
  • 3.3 Exosome CDMO Market: Overall Company Footprint Analysis
    • 3.3.1 Exosome CDMO Market: Region Footprint
    • 3.3.2 Exosome CDMO Market: Company Product Type Footprint
    • 3.3.3 Exosome CDMO Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Exosome CDMO Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Exosome CDMO Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Exosome CDMO Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Exosome CDMO Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Exosome CDMO Consumption Value by Type (2021-2032)
  • 6.2 North America Exosome CDMO Market Size by Application (2021-2032)
  • 6.3 North America Exosome CDMO Market Size by Country
    • 6.3.1 North America Exosome CDMO Consumption Value by Country (2021-2032)
    • 6.3.2 United States Exosome CDMO Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Exosome CDMO Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Exosome CDMO Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Exosome CDMO Consumption Value by Type (2021-2032)
  • 7.2 Europe Exosome CDMO Consumption Value by Application (2021-2032)
  • 7.3 Europe Exosome CDMO Market Size by Country
    • 7.3.1 Europe Exosome CDMO Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Exosome CDMO Market Size and Forecast (2021-2032)
    • 7.3.3 France Exosome CDMO Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Exosome CDMO Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Exosome CDMO Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Exosome CDMO Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Exosome CDMO Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Exosome CDMO Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Exosome CDMO Market Size by Region
    • 8.3.1 Asia-Pacific Exosome CDMO Consumption Value by Region (2021-2032)
    • 8.3.2 China Exosome CDMO Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Exosome CDMO Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Exosome CDMO Market Size and Forecast (2021-2032)
    • 8.3.5 India Exosome CDMO Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Exosome CDMO Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Exosome CDMO Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Exosome CDMO Consumption Value by Type (2021-2032)
  • 9.2 South America Exosome CDMO Consumption Value by Application (2021-2032)
  • 9.3 South America Exosome CDMO Market Size by Country
    • 9.3.1 South America Exosome CDMO Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Exosome CDMO Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Exosome CDMO Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Exosome CDMO Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Exosome CDMO Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Exosome CDMO Market Size by Country
    • 10.3.1 Middle East & Africa Exosome CDMO Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Exosome CDMO Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Exosome CDMO Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Exosome CDMO Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Exosome CDMO Market Drivers
  • 11.2 Exosome CDMO Market Restraints
  • 11.3 Exosome CDMO Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Exosome CDMO Industry Chain
  • 12.2 Exosome CDMO Upstream Analysis
  • 12.3 Exosome CDMO Midstream Analysis
  • 12.4 Exosome CDMO Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Exosome CDMO. Industry analysis & Market Report on Exosome CDMO is a syndicated market report, published as Global Exosome CDMO Market 2026 by Company, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Exosome CDMO market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,690.04
    		4,035.06
    		5,380.08
    		3,239.88
    		4,859.82
    		6,479.76
    		531,361.20
    		797,041.80
    		1,062,722.40
    		293,712.00
    		440,568.00
    		587,424.00
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo